FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Equine Vet J / Five- versus seven-day dosing intervals of extended-release ...
Equine veterinary journal2023; doi: 10.1111/evj.13938

Five- versus seven-day dosing intervals of extended-release injectable omeprazole in the treatment of equine squamous and glandular gastric disease.

Abstract: An extended-release injectable omeprazole formulation (ERIO) has become a popular treatment for equine squamous gastric disease (ESGD) and equine glandular gastric disease (EGGD) where it is available; however, published data are limited and optimal treatment regimens have not been determined. Objective: To compare effects of treatment on ESGD and EGGD when an ERIO formulation is administered at either 5- or 7-day intervals. Methods: Retrospective clinical study. Methods: Case records and gastroscopy images of horses with ESGD or EGGD treated with ERIO were reviewed. Images were anonymised and graded by one researcher masked to treatment group. Treatment responses were compared between the two treatment schedules using univariable ordered logistic regression. Results: Forty-three horses were treated with ERIO at 5-day intervals and 39 horses at 7-day intervals. Signalment and presenting signs did not differ between groups. The proportions of horses with EGGD healing (to grade 0 or 1) in association with ERIO used at 5-day intervals (93%) were higher than associated with treatment at 7-day intervals (69%; odds ratio [OR]: 2.41, 95% CI: 1.23-4.74, p = 0.01). For ESGD, there was no significant difference in the proportion of horses healing in association with treatment at 5-day intervals (97%) compared with 7-day intervals (82%; OR: 2.75, 95% CI: 0.91-8.31, p = 0.07). Four of 328 injections were associated with an injection-site reaction (1%). Conclusions: Retrospective study design, lack of randomisation and limited case numbers. Conclusions: The use of ERIO at 5-day intervals might be more appropriate than the 7-day interval that is used currently. Unassigned: Eine injizierbare Omeprazolformulierung mit verlängerter Wirkstofffreisetzung (ERIO) hat sich zu einer beliebten Behandlungsmethode für die Equine Squamous Gastric Disease (ESGD) und die Equine Glandular Gastric Disease (EGGD) bei Pferden entwickelt, wo sie verfügbar ist. Die veröffentlichten Daten sind jedoch begrenzt und optimalen Behandlungsschemata wurden nicht ermittelt. Unassigned: Vergleich der Auswirkungen der Behandlung auf ESGD und EGGD, wenn eine ERIO-Formulierung entweder in Abständen von fünf oder sieben Tagen verabreicht wird. Methods: Retrospektive klinische Studie. Methods: Fallberichte und Gastroskopiebilder von Pferden mit ESGD oder EGGD, die mit ERIO behandelt wurden, wurden überprüft. Die Bilder wurden anonymisiert und von einem der Autoren blind bewertet. Das Ansprechen auf die Behandlung wurde anhand einer univariablen geordneten logistischen Regression zwischen den beiden Behandlungsschemata verglichen. Unassigned: Dreiundvierzig Pferde wurden im Abstand von fünf Tagen und 39 im Abstand von sieben Tagen mit ERIO behandelt. Das Signalement und die Vorstellungsgründe unterschieden sich nicht zwischen den Gruppen. Der Anteil der Pferde mit einer Heilung der EGGD (auf Grad 0 oder 1) in Verbindung mit einer ERIO-Behandlung im Abstand von fünf Tagen (93%) war höher als bei einer Behandlung im Abstand von sieben Tagen (69%; odds ratio (OR): 2,41 95% CI: 1,23-4,74, p = 0,01). Bei der ESGD gab es keinen signifikanten Unterschied im Anteil der Pferde, die in Verbindung mit einer Behandlung im Abstand von fünf Tagen (97%) im Vergleich zu sieben Tagen (82%) heilten (OR: 2,75, 95% CI: 0,91-8,31, p = 0,07). Bei vier von 328 Injektionen kam es zu einer Reaktion an der Injektionsstelle (1%). Unassigned: Retrospektives Studiendesign, fehlende Randomisierung und begrenzte Fallzahlen. Unassigned: Die Verwendung von ERIO in Abständen von fünf Tagen könnte angemessener sein als der derzeitige angewandte Abstand von sieben Tagen.
© 2023 EVJ Ltd.
Get Full Text
Publication Date: 2023-03-28 PubMed ID: 36977610DOI: 10.1111/evj.13938Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The study evaluates the impact of 5-day versus 7-day intervals of extended-release injectable omeprazole (ERIO) treatment for equine squamous gastric disease and equine glandular gastric disease. Results suggest a higher efficacy of the 5-day interval, especially for equine glandular gastric disease.

Research Objective

  • The primary objective of the research was to compare the effects of two different ERIO administration intervals in treating horses with squamous and glandular gastric diseases. Intervals of 5 and 7 days were tested.

Methodology

  • The study was conducted retrospectively, using case records and gastroscopy images of horses treated with ERIO for equine squamous gastric disease (ESGD) or equine glandular gastric disease (EGGD).
  • A total of 43 horses were treated with ERIO at 5-day intervals and 39 horses at 7-day intervals.
  • The images were anonymized and graded by a single blinded researcher. A univariable ordered logistic regression was then used to compare treatment responses between the two groups.

Results

  • The study showed a higher rate of healing in horses with EGGD when treated at 5-day intervals (93%) compared to those treated at 7-day intervals (69%). This suggests that the dosage frequency made a significant difference in successful treatment.
  • For ESGD, there was no significant difference between 5-day (97%) and 7-day intervals (82%).
  • Among the total injections administered, only 1% were associated with an injection-site reaction, indicating the treatment is largely well-tolerated by the horses.

Limitations and Conclusions

  • Despite promising results, this study was retrospective and lacked randomization, which limits the robustness of its conclusions. Moreover, the limited number of cases lowers the statistical power of the results.
  • Nonetheless, the results indicate that ERIO treatment at 5-day intervals might be more effective in treating equine glandular gastric disease when compared to the currently used 7-day interval schedule. However, for squamous gastric disease, both intervals showed comparable results.

Cite This Article

APA
Sundra T, Kelty E, Rendle D. (2023). Five- versus seven-day dosing intervals of extended-release injectable omeprazole in the treatment of equine squamous and glandular gastric disease. Equine Vet J. https://doi.org/10.1111/evj.13938

Publication

Equine veterinary journal
ISSN: 2042-3306
NlmUniqueID: 0173320
Country: United States
Language: English

Researcher Affiliations

Sundra, Tania
  • Avon Ridge Equine Veterinary Services, Brigadoon, Western Australia, Australia.
Kelty, Erin
  • School of Population and Global Health, The University of Western Australia, Crawley, Western Australia, Australia.
Rendle, David
  • EMT Consulting, Tiverton, Devon, UK.

References

This article includes 24 references
  1. Sykes BW, Hewetson M, Hepburn RJ, Luthersson N, Tamzali Y. European College of Equine Internal Medicine Consensus Statement-equine gastric ulcer syndrome in adult horses.. J Vet Intern Med 2015;29(5):1288-99.
  2. Rendle D, Bowen M, Brazil T, Conwell R, Hallowell G, Hepburn R. Recommendations for the management of equine glandular gastric disease.. UK-Vet Equine 2018;2(Sup1):2-11.
  3. Andrews FM, Sifferman RL, Bernard W, Hughes FE, Holste JE, Daurio CP. Efficacy of omeprazole paste in the treatment and prevention of gastric ulcers in horses.. Equine Vet J 1999;31(S29):81-6.
  4. Doucet MY, Vrins AA, Dionne R, Alva R, Ericsson G. Efficacy of a paste formulation of omeprazole for the treatment of naturally occurring gastric ulcers in training standardbred racehorses in Canada.. Can Vet J 2003;44(7):581-5.
  5. Lester GD, Smith RL, Robertson ID. Effects of treatment with omeprazole or ranitidine on gastric squamous ulceration in racing Thoroughbreds.. J Am Vet Med Assoc 2005;227(10):1636-9.
  6. Murray M, Haven M, Eichorn E, Zhang D, Eagleson J, Hickey G. Effects of omeprazole on healing of naturally-occurring gastric ulcers in Thoroughbred racehorses.. Equine Vet J 1997;29(6):425-9.
  7. Sykes BW, Sykes KM, Hallowell GD. A comparison of three doses of omeprazole in the treatment of equine gastric ulcer syndrome: a blinded, randomised, dose-response clinical trial.. Equine Vet J 2013;47(3):285-90.
  8. Sykes BW, Sykes KM, Hallowell GD. A comparison of two doses of omeprazole in the treatment of equine gastric ulcer syndrome: a blinded, randomised, clinical trial.. Equine Vet J 2013;46(4):416-21.
  9. Rendle D, Hallowell G. Treatment of equine glandular gastric disease in elite endurance horses with oral and long-acting injectable omeprazole: a randomised, blinded clinical trial.. In: Proceedings of the European College of Equine Internal Medicine Congress, Valencia, Spain. 2019.
  10. Pickles KJ, Black K, Brunt O, Crane M. Retrospective study of misoprostol treatment of equine glandular gastric disease.. In: Proceedings of the European College of Equine Internal Medicine Congress; Online, 2020.
  11. Varley G, Bowen IM, Habershon-Butcher JL, Nicholls V, Hallowell GD. Misoprostol is superior to combined omeprazole-sucralfate for the treatment of equine gastric glandular disease.. Equine Vet J 2019;51(5):575-80.
  12. Kranenburg LC, Scheepbouwer JHT, van den Boom R. Retrospective study of combined sucralfate and omeprazole therapy compared with omeprazole monotherapy for equine glandular disease.. In: Proceedings of the European College of Equine Internal Medicine Congress; Online, 2020.
  13. Hepburn RJ, Proudman CJ. Treatment of ulceration of the gastric glandular mucosa: retrospective evaluation of omeprazole and sucralfate combination therapy in 204 sport and leisure horses (Abstract).. In: Proceedings of the International Colic Symposium. Dublin, Ireland; 2014.
  14. Gough S, Hallowell G, Rendle D. Evaluation of the treatment of equine glandular gastric disease with either long-acting-injectable or oral omeprazole.. Vet Med Sci 2022;8(2):561-7.
  15. Sykes BW, Kathawala K, Song Y, Garg S, Page SW, Underwood C. Preliminary investigations into a novel, long-acting, injectable, intramuscular formulation of omeprazole in the horse.. Equine Vet J 2017;49(6):795-801.
  16. Gough S, Hallowell G, Rendle D. A study investigating the treatment of equine squamous gastric disease with long-acting injectable or oral omeprazole.. Vet Med Sci 2020;6(2):235-41.
  17. Rendle D. Treatment of equine squamous gastric disease in elite endurance horses with oral and long-acting injectable omeprazole: a randomised, blinded clinical trial.. In: Proceedings of the European College of Equine Internal Medicine Congress. Valencia, Spain; 2019.
  18. . Recommendations for the diagnosis and treatment of equine gastric ulcer syndrome (EGUS): the Equine Gastric Ulcer Council.. Equine Vet Educ 1999;11(5):262-72.
  19. Crumpton S, Baiker K, Hallowell G, Habershon-Butcher J, Bowen IM. Diagnostic value of gastric mucosal biopsies in horses with glandular disease: abstracts.. Equine Vet J 2015;47(S48):9.
  20. Bell NJV, Burget D, Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastro-oesophageal reflux disease.. Digestion 1992;51(Suppl 1):59-67.
  21. Lehman ML, Bass L, Gustafson DL, Rao S, O'Fallon ES. Clinical efficacy, safety and pharmacokinetics of a novel long-acting intramuscular omeprazole in performance horses with gastric ulcers.. Equine Vet Educ 2022;34(11):573-80.
  22. Barton A, Merle R, Gehlen H. Efficacy of two oral omeprazole formulations for the therapy of equine gastric ulcer disease.. In: Proceedings of the European College of Equine Internal Medicine Congress; Online, 2021.
  23. Sykes BW. Courses for horses: rethinking the use of proton pump inhibitors in the treatment of equine gastric ulcer syndrome.. Equine Vet Educ 2019;31(8):441-6.
  24. Sykes BW, Underwood C, McGowan CM, Mills PC. The effect of feeding on the pharmacokinetic variables of two commercially available formulations of omeprazole.. J Vet Pharmacol Ther 2015;38(5):500-3.

Citations

This article has been cited 2 times.
  1. Klinck M, Lovett A, Sykes B. Incorporating a Behavioral Medicine Approach in the Multi-Modal Management of Chronic Equine Gastric Ulcer Syndrome (EGUS): A Clinical Commentary. Animals (Basel) 2025 Oct 17;15(20).
    doi: 10.3390/ani15203019pubmed: 41153946google scholar: lookup
  2. Sykes B, Lovett A. Can All Behavioral Problems Be Blamed on Equine Gastric Ulcer Syndrome?. Animals (Basel) 2025 Jan 22;15(3).
    doi: 10.3390/ani15030306pubmed: 39943076google scholar: lookup
Subscribe to our newsletter
Join 99,357 horse owners like you who receive our email updates on horse health and nutrition.